| Literature DB >> 23595000 |
Edilene T Dos Santos1, Mara Lúcia A Pereira, Camilla Flávia P G da Silva, Lourdes C Souza-Neta, Regina Geris, Dirceu Martins, Antônio Euzébio G Santana, Luiz Cláudio A Barbosa, Herymá Giovane O Silva, Giovana C Freitas, Mauro P Figueiredo, Fernando F de Oliveira, Ronan Batista.
Abstract
The purpose of this study was to assess the in vitro antimicrobial activity of alkaloid-enriched extracts from Prosopis juliflora (Fabaceae) pods in order to evaluate them as feed additives for ruminants. As only the basic chloroformic extract (BCE), whose main constituents were juliprosopine (juliflorine), prosoflorine and juliprosine, showed Gram-positive antibacterial activity against Micrococcus luteus (MIC = 25 μg/mL), Staphylococcus aureus (MIC = 50 μg/mL) and Streptococcus mutans (MIC = 50 μg/mL), its influence on ruminal digestion was evaluated using a semi-automated in vitro gas production technique, with monensin as the positive control. Results showed that BCE has decreased gas production as efficiently as monensin after 36 h of fermentation, revealing its positive influence on gas production during ruminal digestion. Since P. juliflora is a very affordable plant, this study points out this alkaloid enriched extract from the pods of Prosopis juliflora as a potential feed additive to decrease gas production during ruminal digestion.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23595000 PMCID: PMC3645758 DOI: 10.3390/ijms14048496
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Antimicrobial activities described for Prosopis juliflora extracts.
| Part used | Extract (Method) | Susceptible Microorganisms | Concentration (MIC) | Reference |
|---|---|---|---|---|
| Leaves | Aqueous (maceration) | 50 g of leaves in 100 mL H2O | [ | |
|
| ||||
| Leaves | Aqueous | Fungi: | [ | |
| | 10 g/mL | |||
| | 7.5 g/mL | |||
| | 10 g/mL | |||
| | 15 g/mL | |||
| | 0.5 g/disc | |||
| | 0.5 g/disc | |||
|
| ||||
| Leaves | Methanolic | Gram-positive Bacteria: | [ | |
| | 1 g/disc | |||
| | ||||
| | ||||
| | ||||
| | 10 g/disc | |||
| Gram-negative Bacteria: | ||||
| | 1 g/disc | |||
| | ||||
| | ||||
| | ||||
| Fungi: | ||||
| | 30 g/disc | |||
| | 30 g/disc | |||
| | 40 g/disc | |||
| | 20 g/disc | |||
|
| ||||
| Leaves | Hydroalcoholic (maceration) | 50 mg dried leaves/disc | [ | |
|
| ||||
| Pods | Alkaloid Rich Fraction | Gram-negative Bacteria: | [ | |
| | 75 g/mL | |||
| | 75 g/mL | |||
| | 50 g/mL | |||
|
| ||||
| Pods | Basic Chloroformic | Gram-positive Bacteria: | Present study | |
| | 25 g/mL | |||
| | 50 g/mL | |||
| | 50 g/mL | |||
Through acid-base fractionation for obtaining alkaloid-enriched extracts. MIC, minimum inhibitory concentration.
Antimicrobial activities described for isolated Prosopis juliflora alkaloids.
| Alkaloid | Part | Susceptible Microorganisms | Concentration | Reference |
|---|---|---|---|---|
| Julifloricine | Leaves | Gram-positive Bacteria: | [ | |
| | 1 g/mL | |||
| | ||||
| | ||||
| | ||||
| | ||||
| | 5 g/mL | |||
| | ||||
| | ||||
| | ||||
| | ||||
| | ||||
| Fungi: | ||||
| | 2.5 g/mL | |||
| | 1.0 g/mL | |||
|
| ||||
| Juliprosinene | Leaves | Bacteria: | [ | |
| | ||||
| | ||||
| | N.D. | |||
| | ||||
| | ||||
|
| ||||
| Juliflorine (Juliprosopine) | Leaves | Gram-positive Bacteria: | [ | |
| | 1 to 30 g/mL | |||
| | ||||
| | ||||
| | ||||
| | ||||
| | ||||
| Fungus: | 0.5 to 5 g/mL | |||
| Dermatophyte Fungi | 2.5 g/mL | |||
| Protozoa: | ||||
| | 10 g/mL | |||
N.D., not described.
Figure 1Acid-base fractionation of the ethanolic extract directed to isolation of alkaloids. Adapted from [40].
Minimum inhibitory concentration (MIC, μg/mL) for basic chloroformic (BCE) and basic ethyl acetate (BAE) extracts of P. juliflora pods against some microorganisms.
| Microorganisms | BCE | BAE | Chloramphenicol | Loprox |
|---|---|---|---|---|
| 25 | >100 | 0.8 | - | |
| 50 | >100 | 6.3 | - | |
| 50 | >100 | 6.3 | - | |
| >100 | >100 | 6.3 | - | |
| >100 | >100 | 3.1 | - | |
| >100 | >100 | 6.3 | - | |
| >100 | >100 | 100 | - | |
| >100 | >100 | - | 12.5 | |
| >100 | >100 | - | 6.3 | |
| >100 | >100 | - | 6.3 |
Positive control for bacteria;
Ciclopirox olamine, positive control for fungi.
Comparison of 13C NMR data (δ in ppm, 50 MHz, CDCl3) obtained for BCE with those reported in the literature for juliprosopine (1), prosoflorine (2) and juliprosine (3).
| Carbon | Literature [ | BCE | ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| 1 | 2 | 3 | 1 | 2 | 3 | |
| 1″″ | 33.2 | 32.4 | 32.4 | 33.2 | 32.3 | 32.3 |
| 2″″ | 21.5 | 21.3 | 21.4 | 21.4 | 21.3 | 21.4 |
| 3″″ | 54.5 | 59.8 | 59.8 | 54.5 | 60.5 | 59.8 |
| 5″″ | 55.3 | 138.9 | 139.0 | 55.2 | 138.7 | 138.9 |
| 6″″ | 136.3 | 139.1 | 139.0 | 136.0 | 138.9 | 138.9 |
| 7″″ | 123.8 | 144.0 | 144.0 | 123.9 | 143.9 | 143.9 |
| 8″″ | 42.6 | 141.9 | 141.8 | 42.5 | 141.7 | 141.7 |
| 8a″″ | 65.5 | 154.2 | 154.0 | 65.5 | 154.1 | 154.1 |
| 2,2′ | 57.2 | 57.3 | 57.2 | 57.1 | 57.1 | 57.1 |
| 3,3′ | 67.8 | 67.6, 77.3 | 67.2 | 67.7 | 67.7, 77.4 | 67.3 |
| 4,4′ | 32.2 | 32.0, 31.7 | 31.8 | 32.3 | 31.9, 31.7 | 31.9 |
| 5,5′ | 26.2 | 25.7 | 25.6 | 26.6 | 25.6 | 25.5 |
| 6,6′ | 55.7 | 55.9 | 55.8 | 55.8 | 55.8 | 55.8 |
| 1″,1‴ | 37.1 | 36.2 | 36.1, 36.0 | 36.6 | 36.1 | 36.1, 35.9 |
| 2″,2‴ | 25.8 | 25.6 | 25.1, 25.0 | 25.8 | 25.6 | 25.1, 24.9 |
| 3″,8″ | 30.0–29.4 | 31.9–28.9 | 32.0, 30.8 | 30.0–28.8 | 30.0–28.8 | 31.9, 30.7 |
| 3‴–8‴ | 30.0–29.4 | 31.9–28.9 | 30.5–29.0 | 30.0–28.8 | 30.0–28.8 | 30.0–28.8 |
| 9″,9‴ | 26.6 | 26.6 | ||||
| 10″ | 35.1 | 35.2 | ||||
| 10‴ | 28.0 | 27.9 | ||||
| 7,7′ | 18.7 | 18.1, 17.9 | 18.1, 18.0 | 18.4 | 18.0, 17.9 | 18.0, 17.9 |
N.A., not attributed.
Figure 2Chemical structures of juliprosopine (1), prosoflorine (2) and juliprosine (3).
Figure 3HRESIMS and HPLC-MS analyses of BCE. (A) Direct injection of BCE onto HRESIMS apparatus; (B) HPLC-MS chromatogram obtained for BCE. Chromatographic conditions: see experimental section.
Figure 4Cumulative gas production (mL/g DM) during ruminal fermentation in samples containing increasing concentrations of BCE (i.e., 0, 25, 50, 100 and 200 mg/L) or monensin (Mon, 5 μM), adjusted by the dual-pool model [41].
Kinetics parameters of gas production of samples containing increasing concentrations of BCE (mg/L) or monensin (Mon, 5 μM) after incubation of 36 h.
| Treatment | Kinetic Parameters of Gas Production | ||||
|---|---|---|---|---|---|
|
| |||||
| VFF | KdFF | L | VSF | KdSF | |
| BCE 0 | 43.31 ± 0.69 a | 0.17 ± 0.01 a | 6.55 ± 0.22 c | 96.73 ± 3.46 a | 0.0434 ± 0.0005 c |
| BCE 25 | 38.53 ± 2.58 a | 0.19 ± 0.01 a | 6.93 ± 0.27 b,c | 81.67 ± 13.58 a | 0.0453 ± 0.0005 b,c |
| BCE 50 | 33.75 ± 1.44 a | 0.20 ± 0.01 a | 6.99 ± 0.25 b,c | 90.72 ± 2.38 a | 0.0497 ± 0.0005 b |
| BCE 100 | 34.76 ± 1.21 a | 0.19 ± 0.01 a | 7.16 ± 0.10 b,c | 89.56 ± 2.99 a | 0.04933 ± 0.00009 b |
| BCE 200 | 36.92 ± 3.81 a | 0.16 ± 0.01 a | 8.15 ± 0.54 b | 86.28 ± 7.64 a | 0.0445 ± 0.0019 c |
| Mon | 20.12 ± 0.62 b | 0.26 ± 0.07 a | 10.90 ± 0.32 a | 106.53 ± 1.30 a | 0.056 ± 0.001 a |
Means ± standard deviation. Means followed by the same minuscule letter within each time period did not differ by contrasts (p > 0.05).
VFF, Gas volume for degradation of fast fractions (mL) (p = 0.0001);
KdFF, degradation rate of fast fractions (1/h) (p = 0.2762);
L, lag time (h) (p < 0.0001);
VSF, gas volume for degradation of slow fractions (mL) (p = 0.2128);
KdSF, degradation rate of slow fractions (1/h) (p < 0.0001).
Cumulative gas production (mL/g of DM) of samples containing increasing concentrations of BCE (mg/L) or monensin (Mon, 5 μM) at 6, 12, 18, 24 and 36 h of incubation.
| Treatment | Cumulative Gas Production (mL/g of DM) | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| 6 h | 12 h | 18 h | 24 h | 36 h | ||
| BCE | 0 | 15.31 ± 1.26 a | 60.17 ± 1.52 a | 91.76 ± 1.75 a | 114.22 ± 2.63 a | 137.79 ± 2.80 a |
| 25 | 11.00 ± 2.08 b | 53.23 ± 2.06 b | 81.21 ± 3.61 b | 100.44 ± 5.80 b,c | 120.89 ± 7.70 b | |
| 50 | 11.52 ± 0.67 b | 52.92 ± 1.07 b | 83.39 ± 0.67 b | 106.15 ± 1.07 b | 124.28 ± 1.31 b | |
| 100 | 10.81 ± 0.55 b | 51.66 ± 1.62 c | 82.89 ± 2.21 b | 105.64 ± 2.61 b | 123.48 ± 2.96 b | |
| 200 | 8.73 ± 1.39 c | 40.31 ± 3.10 d | 74.79 ± 2.75 b | 97.27 ± 3.75 c | 120.32 ± 4.00 b | |
| Mon | 2.69 ± 0.36 d | 24.78 ± 1.88 e | 61.84 ± 1.98 c | 96.51 ± 1.53 c | 126.08 ± 1.19 b | |
Means ± standard deviation. Means followed by the same minuscule letter within each time period did not differ by contrasts (p > 0.05). Analysis of variance (Treatment: p < 0.0001, Time: p < 0.0001, Time × treatment: p < 0.0001).
True dry matter degradability (TDDM, g/100 g DM) of samples containing increasing concentrations of BCE (mg/L) or monensin (Mon, 5μM), after incubation of 18 and 36 h.
| Treatment | TDDM (g/100 g DM) | |
|---|---|---|
|
| ||
| 18 h | 36 h | |
| BCE 0 | 69.25 ± 0.81 a | 72.72 ± 0.34 a |
| BCE 25 | 70.61 ± 0.63 a | 71.77 ± 1.34 a |
| BCE 50 | 69.54 ± 0.65 a | 73.07 ± 0.11 a |
| BCE 100 | 69.15 ± 0.64 a | 72.38 ± 0.35 a |
| BCE 200 | 65.73 ± 0.42 b | 71.41 ± 0.04 a |
| Mon | 57.04 ± 0.23 c | 62.21 ± 0.58 b |
Means ± standard deviation. Means followed by the same minuscule letter within each time period did not differ by contrasts (p > 0.05). Analysis of variance (Time: p < 0.0001, Time × treatment: p < 0.0178).
Dry microbial mass production (DMMP, mg/100mg degradable DM) of samples containing increasing concentrations of BCE (mg/L) or monensin (Mon, 5μM), after incubation for 18 and 36 h.
| Treatment | DMMP (mg/100 mg Degradable DM) | |
|---|---|---|
|
| ||
| 18 h | 36 h | |
| BCE 0 | 16.08 ± 0.72 a | 7.69 ± 0.62 a |
| BCE 25 | 18.85 ± 1.38 a | 8.46 ± 0.33 a |
| BCE 50 | 12.50 ± 0.05 b | 8.40 ± 0.24 a |
| BCE 100 | 12.32 ± 0.70 b | 8.71 ± 1.95 a |
| BCE 200 | 11.81 ± 0.10 b | 10.93 ± 2.06 a |
| Mon | 23.90 ± 0.64 a | 18.01 ± 1.64 b |
Means ± standard deviation. Means followed by the same minuscule letter within each time period did not differ by contrasts (p > 0.05). Analysis of variance (Time: p < 0.0001, Time × treatment: p < 0.0273).